Skip to content
ContentLora

    Tip: press / anywhere to search.

    ● Developing story

    Flu season 2026-27 tracker: vaccine strains, subclade K, surveillance

    All three strains in the 2026-27 northern hemisphere flu vaccines were changed, including a new H3N2 strain from subclade K, the variant that was poorly matched by the 2025-26 vaccine.[1][2] By the week ending 7 November 2026, US flu activity was still rising earlier than usual, mostly from A(H1N1)pdm09, while in late October the EU/EEA reported low but increasing influenza.[3][4][5]

    Editor reviewedStrict sourcingUpdated Developing35 claims · 100% primary11 entries · last entry Next check Nov 28, 2026Infectious disease, Health and medicine, mRNA and next-gen vaccines

    What we know

    • WHO's 2026-27 northern hemisphere recommendation changed all three vaccine components from 2025-26[1]
    • The new H3N2 strains, A/Darwin/1454/2025 (egg) and A/Darwin/1415/2025 (cell), are subclade K viruses[2]
    • VRBPAC voted 7-0 for both US formulations on 12 March 2026[7]
    • The EMA's final EU list matches WHO's strains and includes no B/Yamagata strain[11]
    • The entire projected US 2026-27 supply is trivalent[9]
    • US subtyped influenza A from 4 October to 7 November: 4,063 A(H1N1)pdm09 versus 48 A(H3N2)[4]
    • 104 of 109 US H3N2 viruses characterised since 24 May are subclade K[24]
    • All 35 US H3N2 viruses antigenically characterised so far were well recognised by antisera to the 2026-27 cell-based vaccine strain[25]

    What we don't know yet

    • Which subtype will dominate the US and European seasons once activity peaks
    • How well the 2026-27 vaccines will protect; interim effectiveness estimates usually come later in the season
    • Whether the unusually diverse A(H1N1)pdm09 viruses affect how well the H1N1 vaccine component protects
    • Whether H3N2 viruses drift further from the subclade K vaccine strains during the season
    • Whether the early US rise leads to a larger or more severe season; the CDC says it does not necessarily

    This tracker follows the 2026-27 northern hemisphere flu season: the vaccine strains chosen for it and official surveillance from the US CDC and the European Centre for Disease Prevention and Control. It covers data published up to 13 November 2026 and is updated as new weekly reports appear. It is not medical advice. For vaccination decisions, talk to a clinician or pharmacist and check your national health agency’s guidance.

    The 2026-27 northern hemisphere flu vaccines contain three new strains, including an H3N2 strain from subclade K, a variant that antibodies against the 2025-26 vaccine recognised poorly.[1][2] In the US, as of the week ending 7 November 2026, activity was higher than usual for the time of year, but most viruses were A(H1N1)pdm09 rather than H3N2.[3][4]

    The 2026-27 vaccine strains

    On 27 February 2026, WHO recommended that egg-based vaccines contain A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1454/2025 (H3N2)-like and B/Tokyo/EIS13-175/2025 (B/Victoria)-like viruses. For cell-based, recombinant and nucleic acid vaccines, it recommended A/Missouri/11/2025, A/Darwin/1415/2025 (H3N2) and B/Pennsylvania/14/2025 (B/Victoria).[6] All three components differ from the 2025-26 northern hemisphere vaccine.[1]

    In the US, VRBPAC voted 7-0 for each formulation on 12 March 2026, and the FDA issued its recommendations on 13 March. The CDC lists the same strains as WHO.[7][8] The CDC says the entire projected US supply is trivalent.[9]

    The EMA published the EU recommendation on 30 March 2026 and amended it on 7 and 26 May. The last amendment added the cell-based H3N2 strain.[10] The final EU list matches WHO’s. It uses A/Darwin/1454/2025 for egg-based and live attenuated vaccines and A/Darwin/1415/2025 for cell-based vaccines.[11] It includes no B/Yamagata strain, because none has been detected in circulation since March 2020.[12][13] On 25 September 2026, WHO recommended the same strains for the 2027 southern hemisphere season.[14]

    The subclade K concern

    Subclade K viruses are seasonal A(H3N2) viruses that branched off the J.2.4 subclade. They were first classified as J.2.4.1 in October 2025.[15] Between September 2025 and January 2026, they were found in every region and predominated in many countries. Over the same period, global flu detections ran higher than a year earlier and peaked in December 2025.[16][17]

    The FDA’s March 2026 briefing said subclade K viruses were poorly recognised by antibodies against the 2025-26 vaccine strains. Antisera raised against the subclade K Darwin viruses recognised them better.[2] The CDC’s interim 2025-26 estimates put US vaccine effectiveness against hospitalisation at 41% in children and 30% in adults. In the same report, subclade K made up 93% of genetically characterised H3N2 samples.[18][19] VRBPAC members agreed the data were convincing on the need to change all three strains, and discussed adding a second H3N2 strain in future years.[20][21]

    US surveillance so far

    The CDC’s FluView report for the week ending 7 November 2026 said seasonal flu activity was still increasing in many parts of the country and was higher than usual for that time of year.[3] That week, 11.3% of specimens tested by clinical laboratories were positive for flu, and 99.2% of positives were influenza A.[22] A week earlier the positive share was 9.1%.[23] From 4 October to 7 November, public health laboratories subtyped 4,063 A(H1N1)pdm09 viruses and 48 A(H3N2) viruses.[4]

    Of 109 H3N2 viruses collected since 24 May and genetically characterised, 104 were subclade K.[24] All 35 H3N2 viruses tested antigenically were well recognised by ferret antisera against A/Darwin/1415/2025, the H3N2 strain in the 2026-27 cell-based, recombinant and nucleic acid vaccines. These are laboratory comparisons, not estimates of vaccine effectiveness.[25] The CDC said circulating A(H1N1)pdm09 viruses were more genetically diverse than it had seen before, and that it was too early to know which viruses would predominate or whether vaccine effectiveness would be affected.[26]

    The CDC estimated at least 2.6 million illnesses, 36,000 hospitalisations and 2,100 deaths so far this season.[27] Five pediatric deaths had been reported.[28] The CDC still rated severity so far as low across all ages and said an earlier rise does not necessarily mean a higher peak or a more severe season.[29]

    Europe and the rest of the world

    In week 44, ECDC said respiratory illness in the EU/EEA remained at baseline or low levels. Influenza activity was low but increasing in several countries, and SARS-CoV-2 was the main contributor.[5] WHO’s September review of February to August 2026 found influenza A most common in most regions. Influenza B dominated in North America, Eastern Asia and Northern and Western Africa.[30] VRBPAC met on 1 October 2026 to discuss the 2027 southern hemisphere strains.[31]

    How we update this page: we add each new CDC FluView and ECDC weekly report, and interim vaccine effectiveness estimates when they are published. For background, read how flu vaccines are chosen and the flu explainer.

    Timeline

    11 confirmed

    1. confirmed

      US activity keeps rising; CDC estimates 2.6 million illnesses so far[3][27][28]

      Week 44 FluView, published 13 November. Severity was still rated low across all ages.

    2. confirmed

      ECDC reports low but increasing influenza in the EU/EEA[5]

    3. confirmed

      US flu activity rising earlier than usual, mostly H1N1[33][34][35]

    4. confirmed

      VRBPAC meets on 2027 southern hemisphere strains[31]

    5. confirmed

      WHO keeps the same strains for the 2027 southern hemisphere[14][30]

    6. confirmed

      EMA completes amendments with the cell-based H3N2 strain[10][11]

    7. confirmed

      EMA publishes EU 2026/27 recommendation[10][32][12]

    8. confirmed

      FDA issues 2026-27 US composition[8]

    9. confirmed

      FDA advisers back the WHO strains 7-0[7][20]

    10. confirmed

      CDC interim estimates show reduced 2025-26 protection[18][19]

      Effectiveness against hospitalisation was 41% in children and 30% in adults, with subclade K making up 93% of characterised H3N2 samples.

    11. confirmed

      WHO recommends 2026-27 northern hemisphere strains, changing all three[6][1]

      The H3N2 component moves to subclade K viruses (A/Darwin/1454/2025 for egg-based, A/Darwin/1415/2025 for cell-based vaccines).

    Next in the crash course

    More in Infectious disease

    Developing in Health

    Sources

    · 35 claims from 7 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      All three components of the 2026-27 northern hemisphere recommendation differ from the 2025-26 northern hemisphere vaccine, and the H3N2 and B components also differ from the 2026 southern hemisphere vaccine. confirmedas of 2026-02-27

    2. [2]

      The FDA's March 2026 briefing said subclade K viruses were poorly recognised by antibodies against the 2025-26 northern hemisphere vaccine strains, while antisera against the subclade K Darwin viruses recognised them better. confirmedas of 2026-03-10

    3. [3]

      In the week ending 7 November 2026, the CDC said US seasonal flu activity was still increasing in many parts of the country and was higher than usual for that time of year. confirmedas of 2026-11-13

    4. [4]

      Of influenza A viruses subtyped by US public health laboratories from 4 October to 7 November 2026, 4,063 were A(H1N1)pdm09 and 48 were A(H3N2). confirmedas of 2026-11-13

    5. [5]

      In week 44 of 2026, ECDC reported that respiratory illness in the EU/EEA remained at baseline or low levels, with influenza activity low but increasing in several countries and SARS-CoV-2 the main contributor. confirmedas of 2026-11-06

    6. [6]

      On 27 February 2026 WHO recommended that 2026-27 northern hemisphere egg-based vaccines contain A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1454/2025 (H3N2)-like and B/Tokyo/EIS13-175/2025 (B/Victoria)-like viruses, and that cell, recombinant and nucleic acid vaccines use A/Missouri/11/2025, A/Darwin/1415/2025 (H3N2) and B/Pennsylvania/14/2025 (B/Victoria). confirmedas of 2026-02-27

    7. [7]

      On 12 March 2026 the FDA's VRBPAC voted 7-0 for the WHO-recommended egg-based strains and 7-0 for the cell- and recombinant-based strains for US 2026-27 vaccines. confirmedas of 2026-03-12

    8. [8]

      The FDA made its 2026-27 US flu vaccine composition recommendations on 13 March 2026, and the CDC lists the same egg-based and cell or recombinant strains as WHO. confirmedas of 2026-09-29

      • 2026-2027 Flu Season · US Centers for Disease Control and Prevention · Primary source · 2026-09-29 · Vaccine composition (verified in browser 2026-11-07) (retrieved 2026-11-07)
    9. [9]

      The CDC says 100% of the projected US flu vaccine supply for 2026-27 is trivalent (three-component). confirmedas of 2026-09-29

      • 2026-2027 Flu Season · US Centers for Disease Control and Prevention · Primary source · 2026-09-29 · Vaccine supply (verified in browser 2026-11-07) (retrieved 2026-11-07)
    10. [10]

      The EMA first published its 2026/27 recommendation on 30 March 2026, added egg-derived and live attenuated strains on 7 May, and added the cell-derived H3N2 strain and the live attenuated B strain on 26 May. confirmedas of 2026-05-26

    11. [11]

      The EMA's final 2026/27 EU recommendation, amended twice in May 2026, matches WHO's strains, including A/Darwin/1454/2025 for egg-based and live attenuated vaccines and A/Darwin/1415/2025 for cell-based vaccines. confirmedas of 2026-05-26

    12. [12]

      The EU 2026/27 recommendation includes no B/Yamagata strain; where quadrivalent vaccines are still required, makers of inactivated vaccines may add the earlier B/Phuket/3073/2013 B/Yamagata strain. confirmedas of 2026-05-26

    13. [13]

      There have been no confirmed detections of circulating B/Yamagata lineage viruses since March 2020. confirmedas of 2026-02-27

    14. [14]

      On 25 September 2026 WHO recommended the same strains for 2027 southern hemisphere vaccines as for the 2026-27 northern hemisphere season. confirmedas of 2026-09-25

    15. [15]

      Subclade K viruses are seasonal A(H3N2) viruses that emerged from the J.2.4 subclade; they were first classed as J.2.4.1 in October 2025 and then renamed subclade K. confirmedas of 2026-02-27

    16. [16]

      Between September 2025 and January 2026, subclade K viruses were detected in all regions and predominated in many countries. confirmedas of 2026-02-27

    17. [17]

      From September 2025 to January 2026, global flu detections were higher than in the same period a year earlier and peaked in December 2025, with influenza A dominant. confirmedas of 2026-02-27

    18. [18]

      Interim CDC estimates for 2025-26 put vaccine effectiveness at 38-41% against outpatient flu visits and 41% against hospitalisation in children, and 22-34% and 30% in adults. confirmedas of 2026-03-12

    19. [19]

      The CDC's interim 2025-26 report said 93% of genetically characterised US A(H3N2) samples were subclade K, an antigenically drifted virus. confirmedas of 2026-03-12

    20. [20]

      VRBPAC members agreed the data were convincing on the need to change the H1N1, H3N2 and B strains for 2026-27. confirmedas of 2026-03-12

    21. [21]

      At the March 2026 VRBPAC meeting, members discussed putting two A(H3N2) strains in future flu vaccines to address ongoing antigenic drift, and acknowledged the regulatory challenges of licensing such four-strain vaccines. confirmedas of 2026-03-12

    22. [22]

      In the week ending 7 November 2026, 11.3% of specimens tested by US clinical laboratories were positive for influenza, and influenza A made up 99.2% of positives. confirmedas of 2026-11-13

    23. [23]

      In the week ending 31 October 2026, 9.1% of specimens tested by US clinical laboratories were positive for influenza, and influenza A made up 98.6% of positives. confirmedas of 2026-11-06

    24. [24]

      Of 109 US A(H3N2) viruses collected since 24 May 2026 and genetically characterised by the CDC, 104 (95.4%) were subclade K. confirmedas of 2026-11-13

    25. [25]

      All 35 US A(H3N2) viruses the CDC had antigenically characterised by week 44 were well recognised by ferret antisera against the A/Darwin/1415/2025-like reference virus used for the 2026-27 cell-based, recombinant and nucleic acid vaccines. confirmedas of 2026-11-13

    26. [26]

      The CDC said circulating A(H1N1)pdm09 viruses showed more genetic diversity than it had seen before, and that it was too early to know which viruses would predominate or whether vaccine effectiveness would be affected. confirmedas of 2026-11-13

    27. [27]

      The CDC estimated at least 2.6 million flu illnesses, 36,000 hospitalisations and 2,100 deaths in the US in the 2026-27 season through 7 November 2026. confirmedas of 2026-11-13

    28. [28]

      Five pediatric flu deaths from the 2026-27 season had been reported in the US by the week ending 7 November 2026. confirmedas of 2026-11-13

    29. [29]

      In its week 44 report, the CDC said an earlier rise in activity does not necessarily lead to a higher peak or a more severe season, and rated severity so far as low across all ages. confirmedas of 2026-11-13

    30. [30]

      From February to August 2026, influenza A was the most common type in most regions, but influenza B dominated in North America, Eastern Asia and Northern and Western Africa. confirmedas of 2026-09-25

    31. [31]

      VRBPAC met on 1 October 2026 to discuss strain selection for 2027 southern hemisphere flu vaccines. confirmedas of 2026-10-01

    32. [32]

      The European Medicines Agency issues EU flu vaccine composition recommendations every year based on WHO's observations; the 2026/27 recommendations were endorsed by its CHMP committee in March 2026, with change applications for centrally authorised vaccines due by 15 June 2026. confirmedas of 2026-05-26

    33. [33]

      In the week ending 31 October 2026, the CDC said US flu activity was increasing in many areas and was higher than usual for that time of year. confirmedas of 2026-11-06

    34. [34]

      Of influenza A viruses subtyped by US public health laboratories since 4 October 2026, 2,653 were A(H1N1)pdm09 and 37 were A(H3N2). confirmedas of 2026-11-06

    35. [35]

      The CDC estimated at least 1.7 million flu illnesses, 25,000 hospitalisations and 1,400 deaths in the US in the 2026-27 season through 31 October 2026. confirmedas of 2026-11-06

    Revision history (3)
    1. Added CDC FluView week 44 (ending 7 November), including H3N2 antigenic results and H1N1 diversity. ECDC's week 45 update could not be fetched, so Europe still shows week 44.
    2. Page created.
    3. CDC figures re-checked in a browser; the subclade K count now gives its collection window (since 24 May 2026).

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Nov 28, 2026.

    Cite this page

    "Flu season 2026-27 tracker: vaccine strains, subclade K, surveillance." ContentLora, updated Nov 14, 2026. https://contentlora.com/events/flu-season-2026-27-tracker

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.